Main Content


Study title

Phase 3, randomized study of intravenous PI3K inhibitor copanlisib in combination with standard immunochemotherapy versus standard immunochemotherapy in patients with relapsed indolent non-Hodgkin’s lymphoma

  • Principal Investigator: Dr. Stephanie Elkins


This study is looking at the efficacy of an experimental drug in combination with standard immunochemotherapy.

Who can participate 

Those eligible to participate in this study include:

  • Adults 18 years of age and older with indolent Non-Hodgkin’s Lymphoma

For more information

  • Teresa Witcher, RN
    University of Mississippi Medical Center
    2500 N. State St.
    Jackson MS 39216
    (601) 984-6991
  • IRB Number: 2017-0313